14.09.2016 • NewsBASFDede WillamsOleum

BASF to Cut European Caprolactam Output

(c) BASF
(c) BASF

BASF has announced it will cut its European caprolactam production by 100,000 t/y to 400,000 t/y in response to what it called “a difficult market environment.” Most of the capacity reduction is planned to take place at the main site in Ludwigshafen, Germany, where the 80 workers affected by the full or partial closure of four plants producing caprolactam as well as anolone and oleum will be offered new jobs.

The world’s largest chemical producer, which is also Europe’s leading producer of polyamide, for which caprolactam is one of the principal feedstocks, said the closures will take place gradually over the next 18 months.

Goal of the capacity cutbacks is to enhance the competitiveness of the PA 6 value chain, said Joachim Queisser, who heads BASF’s European business unit Polyamides and Precursors. He added that the realignment is also designed to give the group greater flexibility in managing its capacities and allow it to better respond to changing market conditions. Due to overcapacity, demand for PA feedstocks has been weak for some time. In 2013, BASF reduced its capacity for adipic acid, the main feedstock for PA 6.6, by more than 20% to 210,000 t/y.

The Ludwigshafen group operates production facilities for products along the PA chain in Europe, North America and China. European plants are located at Antwerp, Belgium, alongside Ludwigshafen. Freeport, Texas, is home to US production and Shanghai is the Chinese base.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.